Bristol Myers Squibb

Error creating thumbnail:

Bristol Myers Squibb

History

Bristol_Myers_Squibb, (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Some of the popular pharmaceutical products from BMS include:

Error creating thumbnail:

• Abecma (idecabtagene vicleucel)
• Abraxane (paclitaxel)
• Breyanzi (lisocabtagene maraleucel)
• Eliquis (apixaban)
• Empliciti (elotuzumab)
• Inrebic (fedratinib)
• Onureg (azacitidine)
• Opdivo (nivolumab)
• Orencia (abatacept)
• Plavix (clopidogrel)
• Pomalyst/Imnovid (pomalidomide)
• Reblozyl (luspatercept-aamt)
• Revlimid (lenalidomide)
• Sprycel (dasatinib)
• Yervoy (ipilimumab)
• Zeposia (ozanimod)

Leadership

Founded 1887 by William McLaren Bristol, John Ripley Myers, and E. R. Squibb. Headquarters:430 East 29th Street, New York City, New York, United States

Key people

• Giovanni Caforio, M.D. (Chairman & CEO)
• David Elkins (CFO)

Revenue

• BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations.
• As of September 2020, it had total revenue of $39.3 billion.

Error creating thumbnail:

Products

Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.

• Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma. Revlimid as a single agent is also indicated as a maintenance therapy in patients with multiple myeloma following autologous hematopoietic stem cell transplant. Revlimid has received approvals for several indications in the hematological malignancies including lymphoma and MDS.
• Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF and for the treatment ofDVT/PE and reduction in risk of recurrence following initial therapy.
• Opdivo (nivolumab), a biological product, is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells. Opdivo has received approvals for several anti-cancer indications including bladder, blood, colon, head and neck, kidney, liver, lung, melanoma, mesothelioma and stomach. The Opdivo+Yervoy regimen also is approved in multiple markets for the treatment of NSCLC, melanoma, mesothelioma,RCC, and CRC. There are several ongoing potentially registrational studies for Opdivo across other tumor types and disease areas, inmonotherapy and in combination with Yervoy and various anti-cancer agents.
• Pomalyst/Imnovid (pomalidomide) is a small molecule that is administered orally and modulates the immune system and other biologicallyimportant targets. Pomalyst/Imnovid is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
• Orencia (abatacept), a biological product, is a fusion protein indicated for adult patients with moderately to severely active RA and PsA, for reducingsigns and symptoms in certain pediatric patients with moderately to severely active polyarticular JIA and for the treatment of aGVHD, in combination with a calcineurin inhibitor and methotrexate.
• Sprycel (dasatinib) is an oral inhibitor of multiple tyrosine kinase indicated for the first-line treatment of patients with Philadelphia chromosomepositive CML in chronic phase, the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase CML with resistanceor intolerance to prior therapy, including Gleevec (imatinib mesylate) and the treatment of children and adolescents aged 1 year to 18years with chronic phase Philadelphia chromosome-positive CML.
• Yervoy (ipilimumab), a biological product, is a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma.
• Abraxane (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free protein-bound chemotherapy product that combinespaclitaxel with albumin using our proprietary Nab technology platform, and is used to treat breast cancer, NSCLC and pancreatic cancer,among others.
• Reblozyl (luspatercept-aamt), a biological product, is an erythroid maturation agent indicated for the treatment of anemia in adult patients with betathalassemia who require regular red blood cell transfusions and for the treatment of anemia failing an erythropoiesis stimulating agent(“ESA”) in adult patients with very low- to intermediate-risk MDS who have ring sideroblasts and require RBC transfusions. Empliciti Empliciti (elotuzumab), a biological product, is a humanized monoclonal antibody for the treatment of multiple myeloma.
• Abecma (idecabtagene vicleucel) is a B-cell maturation antigen-directed genetically modified autologous CAR T cell therapy indicated for thetreatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including animmunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
• Zeposia (ozanimod) is an oral immunomodulatory drug used to treat moderately to severely active UC and relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.Breyanzi Breyanzi (lisocabtagene maraleucel) is a CD19-directed genetically modified autologous CAR T cell therapy indicated for the treatment of adultpatients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-celllymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphomagrade 3B.
• Inrebic (fedratinib) is an oral kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (postpolycythemia vera or post-essential thrombocythemia) myelofibrosis.
• Onureg (azacitidine) is an oral hypomethylating agent that incorporates into DNA and RNA, indicated for continued treatment of adult patients withAML who achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy.

Research and development

BMS has research and development facilities all over the world. BMS's primary R&D sites are located in the following cities:

• Lawrence, New Jersey (formerly Squibb, near Princeton),
• Summit, New Jersey, formerly HQ of Celgene,
• New Brunswick, New Jersey,
• Redwood City, California, and
• Boudry in Switzerland,
• Devens and Cambridge, Massachusetts,
• East Syracuse, New York,
• Braine-l'Alleud, Belgium,
• Tokyo, Japan,
• Bangalore, India, and
• Wirral, United Kingdom.

BMS previously had an R&D site in Wallingford, Connecticut (formerly Bristol-Myers)

Products under development

• Beclabuvir (BMS-791325) – phase III
• BMS-906024 – phase I
• BMS-955176 – phase II
• Brivanib alaninate (BMS-582664) – development terminated
• Elotuzumab (BMS-901608) – phase III
• Lirilumab (BMS-986015)
• Lulizumab pegol (BMS-931699) – phase II